RaySearch Lab receives two new orders for its RayStation treatment planning system

NewsGuard 100/100 Score

RaySearch Laboratories AB has received two new orders for its RayStation® treatment planning system.

The first order comes from a Canadian cancer care and research facility. They will use RayStation® as a research tool for the development of an exciting new treatment machine that combines a traditional linear accelerator with a Magnetic Resonance Imaging scanner. As MR imaging offers better image quality of soft tissue than standard Computed Tomography this development has the potential to significantly improve the accuracy of radiation treatments.

The other order comes from Clinique de Genolier in Switzerland. This clinic will primarily use RayStation® for the clinical introduction of dose tracking, which is a tool that uses daily imaging data and advanced deformation algorithms to monitor the delivered radiation dose. This enables the clinician to accurately calculate the accumulated dose taking into account changes occurring in the patient's anatomy during the course of treatment.

"Even though these orders have a relatively limited financial impact they are highly important for us as they are the first RayStation® orders from these two regions. The fact that both clinics have selected RayStation® for cutting-edge research further strengthens RaySearch's position as the leading supplier of advanced treatment planning solutions," says Johan Löf, CEO of RaySearch.

RayStation® integrates all RaySearch's advanced treatment planning solutions into one flexible treatment planning system. It combines unique features such as multi-criteria optimization tools with full support for 4D adaptive radiation therapy. It also includes functionality such as RaySearch's market-leading algorithms for IMRT and VMAT optimization and highly accurate dose engines for both photon and proton therapy. The system is built on the latest software architecture and has a graphical user interface offering state-of-the-art usability.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Three early-phase clinical studies show promising initial data for patients with lymphoma, gastric cancers